Drugmaker Eli Lilly And Co LLY announced on Thursday a new website that allows patients to get a weight loss drug prescription through a telehealth provider.
LillyDirect offers disease management resources, including access to independent healthcare providers, tailored support and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.
In November, the FDA approved the company’s Zepbound (tirzepatide) for obesity treatment.
Also Read: Obesity/Diabetes Drug Class GLP-1s’ Cost-Saving Potential: Decoding Impact on Healthcare Spending.
Lilly said its direct-to-consumer service would also be available for patients with diabetes and migraine, with the website’s pharmacy page listing migraine drug Emgality, insulin and similar products for home delivery.
Separately, Lilly issued an open letter noting certain practices regarding diabetes and obesity treatments.
The company said that Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for — and should not be used for — cosmetic weight loss.
In November, a recent analysis by Truveta Research revealed that Eli Lilly’s Mounjaro (tirzepatide) proved more effective for weight loss in overweight or obese adults compared to Novo Nordisk A/S’s NVO Ozempic (semaglutide).
In December, Eli Lilly boosted its quarterly dividend by an impressive 15%, announcing a payout of $1.30 per share for the first quarter of 2024, signaling strong financial confidence.
Related: Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs.
Price Action: LLY shares are up 1.49% at $626.88 on the last check Thursday.
Photo: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
